Aldosterone Synthase Inhibition ± Empagliflozin for Chronic Kidney Disease
The aldosterone synthase inhibitor BI 690517, combined with renin–angiotensin system inhibition and empagliflozin, may have a beneficial role in the treatment of chronic kidney disease,